The AI healthcare market is exploding, projected to reach $500 billion by 2032, and BraineHealth is at the forefront with US Patent 11,908,579 B2. Our Diagnosio platform represents the future of diagnostics, delivering 99% accuracy through inversion technology that powers intelligent, scalable solutions. Rooted in a 2018 KTH thesis, Diagnosio handles 20,000+ cases and 200,000 observables, outperforming tools like Microsoft’s …
In the rapidly evolving world of AI healthcare, BraineHealth’s Diagnosio stands out as a game-changer, powered by our groundbreaking US Patent 11,908,579 B2. This innovation flips traditional diagnostics on its head with inversion technology, which doesn’t just analyze symptoms—it recommends the optimal next step to maximize accuracy and efficiency. At its core, Diagnosio uses neural network-driven probabilistic optimizations to achieve …
BraineHealth AB is thrilled to present US Patent 11,908,579 B2, an AI breakthrough that powers the true virtual doctor of tomorrow. This neural network-driven system inverts traditional diagnostics: rather than just processing symptoms to predict conditions, it intelligently recommends the optimal next test, prompt, or action via probabilistic optimizations (maximizations and minimizations), delivering the most accurate, efficient insights in real …
BraineHealth AB, together with the healthcare provider Citikliniken Sverige AB, has developed the e-health service Citikliniken Labs, which offers health analyzes over the internet for the Swedish market. BraineHealth has developed an e-health service where customers with a simple blood sample can gain more knowledge about their health status. The service, Citikliniken Labs, has been developed together with the healthcare …
